Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envolizumab + Sovalteinib in Treated Bile Duct Cancer
NCT05911425Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Orthosteric Ligands, Nanobodies (VHH)
01
Overview
A Phase 2 trial of envafolimab, surufatinib in cholangiocarcinoma (CCA), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
envafolimabsurufatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05911425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911425.